Related Experiment Video
Updated: Jan 2, 2026
07:28
Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
Published on: April 6, 2017
41.3K
Initial inhaler choice in COPD: real-world evidence
1Dept of Respiratory Medicine, Portsmouth Hospitals NHS Trust, and Faculty of Science, University of Portsmouth, Portsmouth, UK.
Breathe (Sheffield, England)
|December 6, 2019
Summary
For patients with chronic obstructive pulmonary disease (COPD) and high eosinophil counts, starting treatment with inhaled corticosteroids/long-acting beta-agonists (ICS/LABA) reduces exacerbations compared to long-acting muscarinic antagonists (LAMA). This approach does not significantly increase pneumonia risk.
Area of Science:
- Pulmonology
- Respiratory Medicine
- Pharmacotherapy
Background:
- Chronic obstructive pulmonary disease (COPD) management involves selecting appropriate inhaled therapies.
- Peripheral blood eosinophil counts are increasingly recognized as a biomarker for predicting treatment response in COPD.
- The choice between long-acting muscarinic antagonists (LAMA) and inhaled corticosteroid/long-acting beta-agonist (ICS/LABA) combinations is a key clinical decision.
Purpose of the Study:
- To evaluate the comparative effectiveness of initiating inhaled corticosteroid/long-acting beta-agonist (ICS/LABA) versus long-acting muscarinic antagonist (LAMA) therapy in a real-world COPD cohort.
- To assess the impact of these treatment strategies on exacerbation rates and pneumonia incidence, particularly in patients with elevated peripheral blood eosinophils.
Main Methods:
- A real-world cohort study using data from the UK's Clinical Practice Research Datalink (CPRD).
- Analysis compared patients initiating ICS/LABA versus LAMA.
- Stratification by peripheral blood eosinophil counts (>4%) was performed to assess treatment effects in specific subgroups.
Main Results:
- Initiating ICS/LABA therapy in COPD patients with peripheral blood eosinophil counts >4% was associated with a lower rate of exacerbations compared to initiating LAMA.
- No significant increase in pneumonia rates was observed in the ICS/LABA group compared to the LAMA group within this eosinophilic subgroup.
- Real-world data supports the use of ICS/LABA in eosinophilic COPD patients for exacerbation risk reduction.
Conclusions:
- In COPD patients with peripheral blood eosinophil counts >4%, initiating ICS/LABA is a preferred strategy over LAMA for reducing exacerbation frequency.
- This treatment approach offers a favorable safety profile regarding pneumonia risk in this specific patient population.
- Biomarker-guided therapy selection (eosinophils) can optimize COPD management outcomes.
Related Concept Videos
01:23Inhaled Medications
656
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
656
01:26COPD: Management Using Bronchodilators and Corticosteroids
679
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
679
01:29Chronic Obstructive Pulmonary Disease-V: Management
3.0K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
3.0K
01:30Asthma-IV: Diagnostic and Management
3.0K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.0K
01:20Chronic Obstructive Pulmonary Disease-I: Introduction
3.5K
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
3.5K
01:27Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
3.0K
Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
Medical History
3.0K